Search

Your search keyword '"Mitlak BH"' showing total 73 results

Search Constraints

Start Over You searched for: Author "Mitlak BH" Remove constraint Author: "Mitlak BH"
73 results on '"Mitlak BH"'

Search Results

1. Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE

2. Can the prophylactic use of raloxifene, a selective estrogen-receptor modulator, prevent bone mineral loss and fractures in women with diagnosed osteoporosis or vertebral fractures?

3. Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: Updated recommendations from the group for the respect of ethics and excellence in science

6. Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials.

7. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34).

9. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

11. Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis.

12. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial.

13. Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtend.

14. Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia.

15. FRAX and the effect of teriparatide on vertebral and non-vertebral fracture.

16. The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density.

17. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density.

18. Quality of life in sarcopenia and frailty.

19. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.

20. Is diabetes mellitus a heart disease equivalent in women? Results from an international study of postmenopausal women in the Raloxifene Use for the Heart (RUTH) Trial.

21. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.

22. Femoral strength in osteoporotic women treated with teriparatide or alendronate.

23. Long-term raloxifene for postmenopausal osteoporosis.

24. Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA.

25. Effect of Raloxifene on all-cause mortality.

26. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures.

27. Evaluation of vertebral fracture assessment by dual X-ray absorptiometry in a multicenter setting.

28. Recommendations regarding technical standards for follow-on biologics: comparability, similarity, interchangeability.

29. Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis.

30. Beyond hip: importance of other nonspinal fractures.

31. Osteosarcoma and teriparatide?

32. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis.

34. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.

35. Effectiveness of instant vertebral assessment to detect prevalent vertebral fracture.

36. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.

37. Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from the Group for the Respect of Ethics and Excellence in Science.

38. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy.

39. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.

40. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure.

41. Parathyroid hormone as a therapeutic agent.

42. Pharmacogenomics in endocrinology.

43. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.

44. Selective estrogen receptor modulators: a look ahead.

45. Geographic differences in bone turnover: data from a multinational study in healthy postmenopausal women.

47. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.

48. In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators.

49. Sequential effects of chronic human PTH (1-84) treatment of estrogen-deficiency osteopenia in the rat.

50. The effect of systemically administered PDGF-BB on the rodent skeleton.

Catalog

Books, media, physical & digital resources